Multimodality imaging features of dasatinib-induced pulmonary arterial hypertension.
文献摘要
Dasatinib, a tyrosine kinase inhibitor used to treat chronic myelogenous leukemia, is associated with drug-induced pulmonary arterial hypertension (PAH). We report two cases of dasatinib-induced PAH evaluated using advanced noninvasive multimodality imaging. A comprehensive pulmonary hypertension-targeted computed tomography (CT) protocol showed no structural lung abnormalities or pulmonary embolism. However, CT pulmonary perfusion imaging revealed diffuse heterogeneous hypoperfusion in both lungs, suggesting functional pulmonary circulatory impairment. Myocardial delayed-enhancement CT demonstrated late iodine enhancement and increased extracellular volume at the right ventricular insertion points, indicating myocardial involvement related to right ventricular pressure overload. Cardiac magnetic resonance confirmed right ventricular remodeling, and right heart catheterization (RHC) established precapillary pulmonary hypertension. After discontinuation of dasatinib and initiation of pulmonary vasodilator therapy, one patient achieved partial remission and the other normalization of pulmonary hemodynamics on follow-up RHC. These findings underscore the clinical value of advanced imaging in diagnosing and characterizing drug-induced PAH. Learning objective To understand the clinical significance of noninvasive multimodality imaging, including a comprehensive pulmonary hypertension-targeted computed tomography protocol, in dasatinib-induced pulmonary arterial hypertension and to integrate imaging findings for a systematic assessment of its pathophysiology and clinical presentation.